We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$10.2B
AUM Growth
+$793M
Cap. Flow
+$230M
Cap. Flow %
2.25%
Top 10 Hldgs %
30.33%
Holding
229
New
13
Increased
77
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.7M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$44M
3
IQV icon
IQVIA
IQV
+$40.5M
4
MGNX icon
MacroGenics
MGNX
+$39.5M
5
SAGE
Sage Therapeutics
SAGE
+$39.1M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$222M
2
MRNA icon
Moderna
MRNA
+$47.8M
3
CI icon
Cigna
CI
+$47.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$40.5M
5
DVA icon
DaVita
DVA
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.41%
2 Industrials 0.94%
3 Technology 0.31%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCA icon
51
HCA Healthcare
HCA
$82.3B
$69.1M 0.67%
334,273
-40,290
-11% -$8.21M
GBIO
52
DELISTED
Generation Bio
GBIO
$66.7M 0.65%
247,818
+8,500
+4% +$2.54M
SRRK icon
53
Scholar Rock
SRRK
$6.33B
$66.4M 0.65%
2,297,625
+166,500
+8% +$5.1M
CRL icon
54
Charles River Laboratories
CRL
$10.8B
$65.9M 0.64%
178,270
-10,115
-5% -$3.38M
SILK
55
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$61.9M 0.6%
1,293,759
+134,835
+12% +$6.87M
HOLX
56
DELISTED
Hologic
HOLX
$61M 0.6%
913,752
– –
CI icon
57
Cigna
CI
$74.5B
$60.9M 0.59%
256,742
-191,420
-43% -$47.8M
OMCL icon
58
Omnicell
OMCL
$2.09B
$59.6M 0.58%
393,583
+65,664
+20% +$9.14M
REGN icon
59
Regeneron Pharmaceuticals
REGN
$70.9B
$59M 0.58%
105,660
+69,860
+195% +$35.4M
RVMD icon
60
Revolution Medicines
RVMD
$39.6B
$58.9M 0.57%
1,854,805
+789,035
+74% +$27.5M
PACB icon
61
Pacific Biosciences
PACB
$447M
$57.5M 0.56%
1,643,159
+25,654
+2% +$746K
GMED icon
62
Globus Medical
GMED
$10.5B
$56.6M 0.55%
729,420
+81,911
+13% +$5.82M
BIO icon
63
Bio-Rad Laboratories Class A
BIO
$8.15B
$56.2M 0.55%
87,301
-12,901
-13% -$7.85M
VEEV icon
64
Veeva Systems
VEEV
$31.7B
$53.7M 0.52%
172,647
+19,847
+13% +$5.53M
EXEL icon
65
Exelixis
EXEL
$14.1B
$53.4M 0.52%
2,932,000
-12,500
-0.4% -$292K
MOH icon
66
Molina Healthcare
MOH
$11.7B
$50.3M 0.49%
198,734
-6,500
-3% -$1.63M
PEN icon
67
Penumbra
PEN
$12.5B
$49.9M 0.49%
182,125
+2,250
+1% +$614K
ABMD
68
DELISTED
Abiomed Inc
ABMD
$47.2M 0.46%
151,178
+8,494
+6% +$2.61M
GH icon
69
Guardant Health
GH
$20.7B
$47.1M 0.46%
379,609
+76,743
+25% +$10.3M
TXG icon
70
10x Genomics
TXG
$5.55B
$45.6M 0.44%
232,672
+3,633
+2% +$657K
ZBH icon
71
Zimmer Biomet
ZBH
$17.6B
$45M 0.44%
288,484
– –
MDT icon
72
Medtronic
MDT
$106B
$44.6M 0.44%
359,625
+27,103
+8% +$3.4M
IQV icon
73
IQVIA
IQV
$34.4B
$43M 0.42%
177,400
+175,600
+9,756% +$40.5M
TDOC icon
74
Teladoc Health
TDOC
$1.7B
$42.9M 0.42%
257,948
+3,371
+1% +$546K
BDTX icon
75
Black Diamond Therapeutics
BDTX
$103M
$42.2M 0.41%
3,463,000
+1,220,000
+54% +$24.1M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2021 Portfolio in Review

As of Q2 2021, Bellevue Group held 229 positions worth $10.2B, up 8.4% from $9.45B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q2 2021 filing shows 13 new, 77 increased, 41 reduced and 15 closed positions. Its largest new stake was Adaptive Biotechnologies: 962,352 shares worth $39.3M. The largest sale was Alexion Pharmaceuticals, an estimated $222M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2021 buy was Adaptive Biotechnologies: 962,352 shares worth $39.3M.
  • Bellevue Group added most to Vertex Pharmaceuticals in Q2 2021, an estimated $74.7M increase.
  • Bellevue Group's biggest Q2 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $222M.
  • Bellevue Group fully exited DaVita in Q2 2021, selling an estimated $39.6M.
  • Bellevue Group's ten largest holdings make up 30% of its $10.2B portfolio in Q2 2021.
  • Bellevue Group opened 13 new positions and closed 15 in Q2 2021.
  • Bellevue Group's portfolio value rose 8.4% quarter-over-quarter to $10.2B.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.